Click on the subcategory below to find drug monographs for that particular area.
Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
Acceleron and Celgene announced interim data from the Phase 2a study of sotatercept (ACE-011), demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis.
Janssen Biotech announced that the FDA has approved Sylvant (siltuximab) for the treatment of patients with multicentric Castleman's disease (MCD) who are HIV negative and HHV-8 negative.
The FDA has approved Baxter's BAXJECT III, a new reconstitution system for Advate (Antihemophilic Factor VIII [recombinant]).
Nurse awareness of this treatment option and the patient selection criteria may be a significant ...
Treatment with ipilimumab can prolong survival to more than 10 years in a subgroup of ...
Adding the anti-angiogenic agent nintedanib to docetaxel for the second-line treatment of adenocarcinoma NSCLC provides ...